Vaccine experts are due to meet on Thursday to review the evidence for the third dose of Moderna Shot and recommend it to the FDA.
The panel’s meeting, called the Vaccines and Related Biological Products Advisory Committee, comes as Covid-19 cases drop from high levels of the infectious delta variant in many parts of the country, though they are rising in some states .
Federal health officials are pushing for boosters to maintain immune protection in people who have been previously vaccinated, especially against Delta.
FDA has already approved booster dose of vaccine by Pfizer Inc.
and BioNTech SE for seniors and adults at high risk of Covid-19 who have already received shots and at least six months before their first vaccination.
It has also authorized boosters for Pfizer-BioNtech and Moderna Vaccines for some people with weakened immune systems.
The Biden administration has said that 60 million people will be eligible for Pfizer’s booster shot in the coming weeks.
Adding an additional shot of Moderna would greatly expand the US booster campaign. According to the CDC, more than 69 million people in the US have been fully vaccinated with Moderna’s shot.
Moderna has asked the FDA to authorize a booster that is half the dose of the first two vaccines, and is taken at least six months after the second dose.
In a review posted online ahead of the advisory committee meeting, FDA staff did not take a firm stand on Moderna’s application, and indicated that there may not be enough data to support additional doses.
Staff did not respond to Pfizer’s booster request, which was later granted. FDA staff reviews are part of the normal process before the agency makes a decision to vacate a product.
Advisory panel to meet again on Friday to consider Johnson & Johnson‘s
To review data on second dose application and mixing and matching of vaccines and boosters.
Felicia Schwartz [email protected] . Feather